Two-layer separation-type eye drop containing squalane
First Claim
1. A two-layer separation-type ophthalmic solution comprising an oil-containing layer and an aqueous layer, whereinwhen statically stored, an upper layer consisting of the oil-containing layer and a lower layer consisting of the aqueous layer are formed, the oil-containing layer contains squalane,the aqueous layer contains hyaluronic acid and/or its salt and polyvinyl alcohol, with 0.3 to 0.4 w/v % of hyaluronic acid and/or its salt and 0.025 to 0.1 w/v % of polyvinyl alcohol being present in the ophthalmic solution.
2 Assignments
0 Petitions
Accused Products
Abstract
The purpose of the present invention is to provide a technique for formulating a two-layer separation-type ophthalmic solution in which, during storage, an aqueous layer and an oil-containing layer containing squalane are separated from each other, wherein it is possible to homogeneously disperse the oil-containing layer in the aqueous layer while suppressing foaming by shaking the ophthalmic solution before administration, and the homogeneous dispersed state is maintained in a stable manner at least until administration. A two-layer separation-type ophthalmic solution containing squalane and water, wherein hyaluronic acid and/or a salt thereof and polyvinyl alcohol are contained in the ophthalmic solution and the polyvinyl alcohol content is set to 0.025 to 0.1 w/v %, whereby it is possible to homogeneously disperse the oil-containing layer in the aqueous layer while suppressing foaming by shaking the ophthalmic solution before administration, and to maintain the homogeneous dispersed state in a stable manner at least until administration.
-
Citations
8 Claims
-
1. A two-layer separation-type ophthalmic solution comprising an oil-containing layer and an aqueous layer, wherein
when statically stored, an upper layer consisting of the oil-containing layer and a lower layer consisting of the aqueous layer are formed, the oil-containing layer contains squalane, the aqueous layer contains hyaluronic acid and/or its salt and polyvinyl alcohol, with 0.3 to 0.4 w/v % of hyaluronic acid and/or its salt and 0.025 to 0.1 w/v % of polyvinyl alcohol being present in the ophthalmic solution.
Specification